

Cutter



REF:WE-054

TO: B. Modersbach

DATE: 2 February 1983

FROM: W. Ewald
SUBJECT: AIDS

COPIES TO: J. N. Ashworth

MDL 986

Bud,

The attached illustrates the urgency with which I had approached you last week regarding a statement for AIDS. I am very pleased that our statement went out already last week and was received in time to answer the questions that seem to be cropping up in some of our markets.

As far as the questions from England are concerned, I would appreciate your help in answering them.

Regards,

GRO-C: W.
Ewald

rmb

Enclosure

SMS 008616

DOE 2406

CUTTERITL ENVL

RECEIVED

FEB 2 1987

CUTTER INTERNATIONAL

848337 MILAGE G W. ENALD

FROM: B. BYOS

CC: J N ASHWORTH

DATE: 2.2.87

SUBJ: A I B S

FOLLOWING DISCUSSIONS WITH NENT ASHWORTH DURING HI LAST UK VISIT OVER BRITISH PRESS REPORTS ON AIDS, I WAS PLEASED TO RECEIVE YOUR TELEX JANUARY 28 DETAILING A CUTTER POLICY STATEMENT SHOULD QUESTIONS ARISE FROM DHSS.

FURTHER COMMENT IN THE LANCET ISSUES JAN 22 PAGES 162-164 AND JAN 29 PAGES 213-214 HAVE PROMOTED FURTHER CONCERN IN THE UK.

DR. PETER KERNOFF CO/DIRECTOR OF THE ROYAL FREE HOSPITAL HAEMOPHILIA CENTRE CONTACTED BARRY BARBER FEB 1ST TO REQUEST SOMETHING IN WRITING FROM CUTTER I.E., WHAT ARE CUTTER DOING ABOUT AIDS? DO WE ACCEPT HOMOSEXUAL DONORS? WHERE ARE OUR PLASMA CENTRES SITUATED? HOW MUCH PLASMA FROM SAN FRANCISCO OR NEW YORK AREAS WOULD WE PROCESS? THESE QUESTIONS RELATE DIRECTLY TO RECENT PUBLICITY.

THE ROYAL FREE ACCOUNT WILL UTILIZE APPROX 5 MILLION UNITS COMMERCIAL FVIII THIS YEAR AND CUTTER HAVE BEEN AWARDED HALF THE BUSINESS - SUPPLY TO COMMENCE APRIL. DR KERNOFF WOULD BE COUNTED AMONGST THE TOP SIX IN THE UK HAEMOPHILIA TREATMENT.

I AM WELL ABLE TO BUILD A LETTER AROUND THE FACTS STATED IN THE PROPOSED POLICY LETTER, HOWEVER, IN A COUNTRY WHICH ADVOCATES A VOLUNTARY DONOR SYSTEM, I BELIEVE THE CUTTER PROPOSAL TO CONFRONT REMUNERATED DONORS WITH THE STATEMENT OUTLINED IN THE TELEX WILL BE THOUGHT OF AS A RATHER TAME APPROACH.

THE PRESENT SITUATION ALSO AFFORDS THE TWO UK FRACTIONATORS MR JOHN HATT SCOTLAND AND DR R LANE AT ELSTREE FURTHER A MMUNITION TO PRESSURE GOVERNMENT FOR THEIR GOAL OF UK SELF SUFFICIENCY IN PLASMA PRODUCTS.

SHOULD A COMPANY RESPONSE FROM THE HIGHEST LEVEL BE CONSIDERED FOR PUBLICATION IN A JOURNAL SUCH AS THE LANCET? IT WOULD AT LEAST PUBLICISE THE COMPANY AS BEING ACTIVELY INVOLVED IN THE RESOLUTION OF THE AIDS PROBLEM.

SMS 008617

DOE 2407

117 00 GRO-C

CUTTERITL ENVL

24 1992

84833T MILANS G

GA

TO: BRIAN DYOS

FROM: J. N. ASHNORTH

FEB. 4. 1993

REF. 3.44

THANK YOU FOR SENDING THE INQUIRY OF DR. KERNOFF. WE SUGGEST THAT, IN ADDITION TO THE CUTTER STATEMENT OF POLICY IN THE TELEX OF JANUARY 23, YOU ADD THE FOLLOWING INFORMATION RECORDED AS NEEDED TO FIT YOUR RESPONSE:

THE FIRST TWO QUESTIONS ABOUT OUR POLICY ON ACCEPTANCE OF DONORS IS COVERED BY OUR STATEMENT. THE PROGRAM BEING INSTITUTED IN ALL CUTTER-OWNED AND CONTRACT CENTERS WILL PROVIDE ALL PROSPECTIVE DONORS WITH INFORMATION ON A.I.D.S. AND, IN PARTICULAR ON THE APPARENT BLOOD-RELATED ASPECTS OF A.I.D.S. BEFORE ANY DONATION CAN BE ACCEPTED. THE DONOR IS REQUIRED TO CERTIFY IN WRITING THAT HE OR SHE IS NOT A MEMBER OF THE SPECIFIED HIGH RISK GROUPS, I.E. MALE HOMOSEXUAL, USER OF INTRAVENOUS DRUGS OR A RECENT RESIDENT OR VISITOR TO HAITI.

CUTTER HAS NO CUTTER-OWNED OR CONTRACT CENTERS IN THE CITIES OF NEW YORK, LOS ANGELES OR SAN FRANCISCO. THE CENTERS FROM WHICH WE SECURE PLASMA TEND TO BE GEOGRAPHICALLY DISPERSED THROUGHOUT THE U.S. WITH RESPECT TO AN OBSERVATION THAT OUR APPROACH COULD BE CONSIDERED AS RATHER TAME, IT SHOULD BE NOTED THAT THE A.I.D.S. SITUATION IS A TERRIBLY COMPLEX MIXTURE OF MEDICAL AND SCIENTIFIC MYSTERIES AND, AT THIS POINT, WITH SUBSTANTIAL SOCIAL UNBRAINING. THERE ARE NO ANSWERS TO MANY IMPORTANT QUESTIONS. YOU CAN BE ASSURED THAT CUTTER IS FOLLOWING ALL DEVELOPMENTS WITH GREAT CARE AND WE ARE IN VIRTUALLY CONSTANT COMMUNICATION WITH RESPONSIBLE HEALTH AUTHORITIES ESPECIALLY AS IT CONCERNS OUR SEGMENT OF THE OVERALL A.I.D.S. PROBLEM.

WE WILL BE RESPONSIVE IN OUR DONOR ACCEPTANCE CRITERIA TO SCIENTIFIC AND MEDICAL DEVELOPMENTS AS AND WHEN THEY OCCUR TOGETHER WITH ANY REQUESTS OR REQUIREMENTS OF REGULATORY AGENCIES.

ASHNORTH/CUTTER

11

84833T MILANS G

CUTTERITL ENVL

1997EST 005.23

B. MODERSBACH

H. EHRLD

B. EARDEN

J. HJORTH

A. LEONG

S. OJALA

MFT 000104